Late-Stage Product Acquisition Service (LSPAS)
The Late-Stage Product Acquisition Service (LSPAS) was created to assist companies in the identification of ethical and OTC pharmaceuticals which are launched or in late-stage development and can be acquired for cash and royalties. Late-stage opportunities are typically those products which have completed at least Phase II clinical testing and may be launched in one or more territories. Very often a pharmaceutical compound is only launched in select territories and marketed by the drug innovator. However, opportunities exist for licensing, co-marketing, co-promotion, cross-licensing or quid-pro-quo.
Technology Catalysts International has developed an extensive international network of daily contacts with the pharmaceutical industry based on long-standing presence in and service to these companies.
The service begins with a face-to-face "kick-off" meeting in which the client identifies its specific areas of interest in ethical or OTC pharmaceuticals. This meeting will include confidential discussions covering the needs of the client regarding its financial and territorial objectives, such as launching a product by a certain date and achieving certain sales, the types of opportunities of interest (i.e., licensing or co-marketing), therapeutic classes, and geographic regions. Interviews are then held by TCI with companies and/or research organizations having pharmaceutical products which meet the parameters defined by the client. Client confidentiality is maintained throughout the entire process.
Product descriptions, company contact information, and analyses are gathered into one document three times a year. Whenever possible, these analyses will include competitive advantage statements to allow for a more complete understanding of the product position. No brokerage fees or commissions are ever charged by TCI for successful deals.
